Abstract: The invention discloses for the first time pluripotent cells, including induced pluripotent stem cells, embryonic stem cells, hypo-immune pluripotent cells, cells that have been derived therefrom, and cells that have been biologically differentiated therefrom into particular tissue lineages that are ABO blood type O Rhesus Factor negative or otherwise evade rejection resulting from blood type antigen mismatch. The invention further provides universally acceptable “off-the-shelf” pluripotent cells and derivatives thereof for generating or regenerating specific tissues and organs.

Abstract: The invention provides recombinant CD47 engager receptor proteins comprising an intracellular domain that enhances an immune response in a cell when the CD47 engager receptor protein binds to CD47 on a target cell. The invention also provides cells comprising the CD47 engager receptor proteins. The CD47 engager receptor protein may be a switched Signal Regulatory Protein Alpha (SIRP?) receptor (SIRP? switch receptors) and cells that comprise them (SIRP? switch cells). SIRP? switch receptors recognize CD47 on target tumor cells and transmit an intracellular signal within the SIRP? switch cells that upregulates natural killer cell (NK), T cell, and macrophage activity. The result is increased tumor cell killing.

Abstract: The invention provides, for the first time, cells that express truncated or modified Fc Receptor proteins (e.g. CD16t, CD32t, or CD64t) to evade antibody-dependent cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC). The cells may be pluripotent cells, including hypoimmune pluripotent cells (HIP) or ABO blood type O Rhesus Factor negative HIP cells (HIPO?), that express a truncated or modified Fc Receptor. The invention encompasses cells derived from the pluripotent cells as well as primary cells. The cells may also be differentiated cells, including chimeric antigen receptor (CAR) cells, T cells, natural killer (NK) cells, endothelial cells, dopaminergic neurons, neuroglial cells, pancreatic islet cells, pancreatic beta cells, thyroid cells, fibroblasts, hepatocytes, cardiomyocytes, or retinal pigment endothelium cells.

Abstract: The invention relates to gene therapies using viral vectors. The invention provides, for the first time, packaging cells that comprise enhanced Fc receptor expression (e.g. CD16, CD32, or CD64) to generate gene therapy viruses that evade antibody-dependent inactivation (ADI) or complement-dependent inactivation (CDI). The invention also provides gene therapy viruses with the enhanced Fc receptors displayed on their viral envelope.

Abstract: The invention provides, for the first time, cells that comprise enhanced CD16, CD32, or CD64 expression to evade antibody-dependent cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC). The cells may be pluripotent cells, including hypoimmune pluripotent cells (HIP) or ABO blood type O Rhesus Factor negative HIP cells (HIPO?), that further comprise the enhanced CD16, CD32, or CD64 expression. The invention encompasses cells derived from the pluripotent cells.

Abstract: The invention provides cells that have an increased Signal Regulatory Protein Alpha (SIRP??) engagement function (SIRP? engager cells) that resist innate immunity when transplanted into a subject when compared to a parental cell having an unmodified SIRP? engagement function. The SIRP? engager cells lack an intact CD47 cytoplasmic signalling function. In some embodiments, the SIRP? engager cells are hypoimmune cells. In other embodiments, the SIRP? engager cells are differentiated somatic cells. In other embodiments, the SIRP? engager cells are hypoimmune pluripotent (HIP) cells. In further embodiments, the HIP cells are blood type O (HIPO), Rhesus factor (Rh)negative (HIP?) or both type O and Rh? (HIPO?). In other embodiments, the SIRP? engager cells have been derived or differentiated from HIP, HIP?, or HIPO? cells. In other embodiments, the SIRP? engager cells comprise an antibody Fc receptor to protect against antibody dependent cellular cytotoxicity (ADCC) or complement dependent cytotoxicity (CDC).

Abstract: The invention provides pluripotent cells that are used therapeutically for regenerating tissues but avoid rejection by subjects that receive them. In particular, the invention provides hypo-immunogenic pluripotent cells that avoid host immune rejection. The cells lack major immune antigens that trigger immune responses and are engineered to avoid phagocytic endocytosis. The invention further provides universally acceptable “off-the-shelf” pluripotent cells and derivatives thereof for generating or regenerating specific tissues and organs.

Abstract: The invention provides, for the first time, strategies to inhibit the killing of transplanted cells by activated polymorphonuclear cells (PMNs) of the recipient. Multiple different modes for PMN inhibition are provided and one or more agents effectively utilized every mode of action. The combination of two or more of those agents with different modes of action synergistically improved the efficacy of PMN inhibition without exerting toxic side effects on the survival of the target cells. The cells may be pluripotent cells, including hypoimmune pluripotent cells (HIP), ABO blood type O Rhesus Factor negative HIP cells (HIPO?), or derivatives thereof. The cells may also be alpha 1 antitrypsin (A1AT) secreting cells.

Abstract: The invention provides Natural Killer (NK) cells that have a reduced or ablated Signal Regulatory Protein Alpha (SIRP?-) function when compared to a NK cell having an unmodified SIRP?-function that effectively kills a population of cancer cells that express CD47.

Abstract: The invention discloses for the first time pluripotent cells, including induced pluripotent stem cells, embryonic stem cells, and hypo-immune pluripotent cells that are ABO blood type O Rhesus Factor negative and evade rejection resulting from blood type antigen mismatch. The invention further provides universally acceptable “off-the-shelf” pluripotent cells and derivatives thereof for generating or regenerating specific tissues and organs.

Abstract: The invention discloses for the first time pluripotent cells, including hypoimmune pluripotent ABO blood type O Rhesus Factor negative (HIPO?) cells, that evade rejection by the host allogeneic immune system and avoid blood antigen type rejection. The HIPO? cells comprise reduced HLA-I and HLA-II expression, increased CD47 expression, and a universal blood group O Rh? (“O?”) blood type. The universal blood type is achieved by eliminating ABO blood group A and B antigents as well as eliminating Rh factor expression, or by starting with an O? parent cell line. These new, novel HIPO? cells evade host immune rejection because they have an impaired antigen presentation capacity, protection from innate immune clearance, and lack blood group rejection. The cells of the invention also include O? pluripotent stem cells (iPSCO?) and O? embryonic stem cells (ESCO?).

Abstract: The invention discloses for the first time pluripotent cells, including hypoimmune pluripotent ABO blood type O Rhesus Factor negative (HIPO?) cells, that evade rejection by the host allogeneic immune system and avoid blood antigen type rejection. The HIPO? cells comprise reduced HLA-I and HLA-II expression, increased CD47 expression, and a universal blood group O Rh? (“O?”) blood type. The universal blood type is achieved by eliminating ABO blood group A and B antigents as well as eliminating Rh factor expression, or by starting with an O? parent cell line. These new, novel HIPO? cells evade host immune rejection because they have an impaired antigen presentation capacity, protection from innate immune clearance, and lack blood group rejection. The cells of the invention also include O? pluripotent stem cells (iPSCO?) and O? embryonic stem cells (ESCO?).

Abstract: The invention provides universally acceptable “off-the-shelf” hypoimmune pluripotent (HIP) cells and hypoimmune chimeric antigen receptor T (CAR-T) cells derived from the HIP cells. The engineered therapeutic cells can be administered to subjects as an adoptive cell-based immunotherapy to treat cancer.

Abstract: The invention provides universally acceptable “off-the-shelf” hypoimmunogenic pluripotent cells and differentiated cardiac, endothelial, neuronal, islet, or retinal pigment cells thereof. Such hypoimmune cells are used to treat patients in need thereof. The cells lack major immune antigens that trigger immune responses and are engineered to avoid phagocytic endocytosis.

Abstract: The invention discloses for the first time pluripotent cells, including hypoimmune pluripotent ABO blood type O Rhesus Factor negative (HIPO?) cells, that evade rejection by the host allogeneic immune system and avoid blood antigen type rejection. The HIPO? cells comprise reduced HLA-I and HLA-II expression, increased CD47 expression, and a universal blood group O Rh?(“O?”) blood type. The universal blood type is achieved by eliminating ABO blood group A and B antigents as well as eliminating Rh factor expression, or by starting with an O? parent cell line. These new, novel HIPO? cells evade host immune rejection because they have an impaired antigen presentation capacity, protection from innate immune clearance, and lack blood group rejection. The cells of the invention also include O? pluripotent stem cells (iPSCO?) and O? embryonic stem cells (ESCO?).

Abstract: The invention discloses for the first time pluripotent cells, including induced pluripotent stem cells, embryonic stem cells, hypo-immune pluripotent cells, cells that have been derived therefrom, and cells that have been bioligically differentiated therefrom into particular tissue lineages that are ABO blood type O Rhesus Factor negative or otherwise evade rejection resulting from blood type antigen mismatch. The invention further provides universally acceptable “off-the-shelf” pluripotent cells and derivatives thereof for generating or regenerating specific tissues and organs.

Abstract: The invention provides pluripotent cells that are used therapeutically for regenerating tissues but avoid rejection by subjects that receive them. In particular, the invention provides hypo-immunogenic pluripotent cells that avoid host immune rejection. The cells lack major immune antigens that trigger immune responses and are engineered to avoid phagocytic endocytosis. The invention further provides universally acceptable “off-the-shelf” pluripotent cells and derivatives thereof for generating or regenerating specific tissues and organs.

Abstract: Methods are provided for preventing, inhibiting, or treating intimal hyperplasia in a patient who has undergone a coronary bypass procedure that include providing a solution comprising DCA added to water; and administering the solution orally to a patient to prevent, inhibit, or treat intimal hyperplasia.

Abstract: Methods are provided for preventing, inhibiting, or treating intimal hyperplasia in a patient who has undergone a coronary bypass procedure that include providing a solution comprising DCA added to water; and administering the solution orally to a patient to prevent, inhibit, or treat intimal hyperplasia.

Abstract: Methods are provided for preventing, inhibiting, or treating intimal hyperplasia in a patient who has undergone a coronary bypass procedure that include providing a solution comprising DCA added to water; and administering the solution orally to a patient to prevent, inhibit, or treat intimal hyperplasia.